Feasibility and Safety of Venetoclax for Cytoreduction During Induction Therapy in Newly Diagnosed Acute Promyelocytic Leukemia.
A BCL-2 inhibitor safely reduced leukemia burden during induction therapy in acute promyelocytic leukemia, warranting further study to reduce early deaths.
This single-center retrospective study evaluated the use of venetoclax (BCL-2 inhibitor) as a cytoreductive agent during induction therapy in newly diagnosed APL, demonstrating apparent feasibility and an acceptable safety profile. The exploratory early-efficacy data justify prospective investigation of this combination in APL, where cytoreduction strategies are needed to reduce early mortality.
What the study was
- Study design
- Single-center retrospective study
- Population
- Newly diagnosed acute promyelocytic leukemia (APL) patients receiving venetoclax during induction
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- European journal of haematology
Why it surfaced
Exploratory use of venetoclax in APL induction represents a potentially novel cytoredcution strategy in a disease with high early mortality risk; preliminary feasibility and safety data support hypothesis generation for prospective trials.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.